Therefore, targeting ferroptosis-related protein ACSL4 may shed new light on the therapy of some other CNS diseases, including epilepsy (Kahn-Kirby et al., 2019; Mao et al., 2019; Shao et al., 2020, 2022; Yang et al., 2020; Chen et al., 2022), ALS (Moujalled et al., 2021; Wang T. et al., 2022), cerebral malaria (Liang et al., 2022), bipolar disorder (Modi et al., 2014, 2017), and sepsis-associated encephalopathy (Wang J. et al., 2022). The gene discussed is ACSL4; the disease is bipolar disorder.